Treatment with recombinant human parathyroid hormone (I-34) decreases the severity and sequelae of vertebral fractures

G Goemaere, B. Mitlak(Eli Lilly (United States)), O Wang, Jean‐Marc Kaufman(Ghent University Hospital)

Ghent University Academic Bibliography (Ghent University)

January 1, 2001

Cited by 1

Related Papers

Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy

|Osteoporosis International|2004|320

Evaluation of vertebral fracture assessment by dual X-ray absorptiometry in a multicenter setting

|Osteoporosis International|2008|103

Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO)

|Endocrine|2017|68

The effect of 2 and 3 years of Raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis

|ORBi (University of Liège)|1998|21

Parathyroid hormone as a therapeutic agent

|Current Opinion in Pharmacology|2002|20